ArticleCancer research2026
ARF beyond p53: Shaping the Pancreatic Tumor Microenvironment.
Article in Cancer research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Opportunities in cancer gene therapy: inhibiting MDM2 and restoring p14ARF as a means to activate p53.Molecular and cellular biochemistry · 2026Review
Corrections and comments
- Comment on
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
ARF (p14ARF) is a tumor suppressor classically known for stabilizing and activating p53. In this issue of Cancer Research, Ferreira and colleagues provide insights into the role of ARF in the development of pancreatic ductal adenocarcinoma, showing its p53-independent tumor microenvironment regulatory function. The findings reveal a significant association of ARF loss with stromal remodeling characterized by increased extracellular matrix deposition and fibroblast infiltration. Although further studies are needed to explore the underlying mechanisms and to determine clinical significance, this study has highlighted ARF as a potential upstream regulator of the microenvironment and a candidate therapeutic target. See related article by Ferreira et al., p. 3109.
Indexed as
Identifiers
42388020What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.